Day: March 20, 2024

Posted on

Zoom announces communications compliance solution, Zoom Compliance Manager

Zoom Compliance Manager provides a single integrated platform for risk and compliance management, data governance, and information protection across the Zoom platform, powered by Theta Lake

SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced the launch of Zoom Compliance Manager, an all-in-one offering that provides archiving, eDiscovery, legal hold, and information protection capabilities to help organizations fulfill regulatory requirements and mitigate organizational communications compliance risks across the Zoom platform.

“Zoom currently provides compliance and information protection for enterprise customers within regulated industries like financial services, healthcare, and the public sector through integrations with key communications compliance providers,” said Ritu Mukherjee, head of Product Business Acceleration and Readiness at Zoom. “With Zoom Compliance Manager, we are making it easy for our customers to have an end-to-end experience — seamless buying, easy setup, centralized management, and simplified support — with a comprehensive solution that addresses their communications compliance needs across the Zoom platform.”

Addressing Customer Needs
Organizations today face increasingly stringent regulatory requirements and communications compliance risks both internally and externally, which can result in hefty fines, legal liabilities, and reputation damage. This underscores the critical need for robust compliance solutions that help organizations navigate these challenges. Zoom Compliance Manager powered by Theta Lake allows you to confidently use Zoom while maintaining regulatory requirements.

Key features of Zoom Compliance Manager include:

  • Archiving and Content Capture: Maximize your Zoom usage and meet regulatory and long-term record retention requirements with automatic capture for meetings data, AI summaries, phone recordings, team chat, whiteboard content, and more.
  • eDiscovery: Discover insights across the Zoom platform via a user-friendly interface, facilitating easy access to communication archives and offering the ability to analyze, evaluate, and effortlessly export content.
  • Legal Hold: Capture and hold communications of specific individuals and manage cases through custom workflow, case management, and data export requests when legally mandated.

A future version of Zoom Compliance Manager will include:

  • Risk Detection: Monitor and detect spoken, written, or shared content at scale across supported products using intelligent detection which identify regulatory, privacy, conduct, and security risks in what was said, shown, and shared to mitigate risks.
  • Data Loss Prevention: Identify and mitigate potential risks in your communication workflows using both custom and pre-defined policies through monitoring and thorough analysis.

Zoom Compliance Manager provides compliance capabilities across the Zoom platform, including AI Companion, Meetings, Team Chat, Phone, Whiteboard, Rooms, Webinars, Events, and Contact Center. Zoom Compliance Manager is available as an add-on to Zoom customers with a paid plan.

Support for other Zoom products, including Workvivo, Zoom Revenue Accelerator, Mail, Calendar, and others, will be coming later this year.

Leveraging Theta Lake as a Leader in Compliance and Security

Zoom Compliance Manager integrates the proven compliance solution from Theta Lake, a leader in digital communications governance providing modern communication compliance and security solutions. Through Zoom-specific enhancements, customers will have the compliance benefits of Theta Lake with a frictionless Zoom experience via the administrator console.

“Our expanded compliance and security capabilities for Zoom, along with the ability to use Theta Lake technology, represents a significant milestone in our partnership,” said Anthony Cresci, SVP of GTM and Partnerships at Theta Lake. “With this new offering we are able to provide organizations with seamless and efficient access to communication and collaboration capabilities that have compliance record keeping, archiving, search, supervision, and data protection built in. I am incredibly proud of expanding the value and innovation that our partnership has delivered to our joint customers.”

Experience the Solution

Attendees of Enterprise Connect, taking place March 25-28, are encouraged to visit the Zoom booth (#407) and the Theta Lake booth (#2026). To experience a live demo of Zoom Compliance Manager, visit the Zoom booth on March 26 at 5:30 p.m. EST.

For more information, please visit the Zoom Compliance Manager landing page at https://click.zoom.us/compliance-manager

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Zoom Public Relations
Travis Isaman
press@zoom.us

GlobeNewswire Distribution ID 9066412

Posted on

Zoom announces communications compliance solution, Zoom Compliance Manager

Zoom Compliance Manager provides a single integrated platform for risk and compliance management, data governance, and information protection across the Zoom platform, powered by Theta Lake

SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced the launch of Zoom Compliance Manager, an all-in-one offering that provides archiving, eDiscovery, legal hold, and information protection capabilities to help organizations fulfill regulatory requirements and mitigate organizational communications compliance risks across the Zoom platform.

“Zoom currently provides compliance and information protection for enterprise customers within regulated industries like financial services, healthcare, and the public sector through integrations with key communications compliance providers,” said Ritu Mukherjee, head of Product Business Acceleration and Readiness at Zoom. “With Zoom Compliance Manager, we are making it easy for our customers to have an end-to-end experience — seamless buying, easy setup, centralized management, and simplified support — with a comprehensive solution that addresses their communications compliance needs across the Zoom platform.”

Addressing Customer Needs
Organizations today face increasingly stringent regulatory requirements and communications compliance risks both internally and externally, which can result in hefty fines, legal liabilities, and reputation damage. This underscores the critical need for robust compliance solutions that help organizations navigate these challenges. Zoom Compliance Manager powered by Theta Lake allows you to confidently use Zoom while maintaining regulatory requirements.

Key features of Zoom Compliance Manager include:

  • Archiving and Content Capture: Maximize your Zoom usage and meet regulatory and long-term record retention requirements with automatic capture for meetings data, AI summaries, phone recordings, team chat, whiteboard content, and more.
  • eDiscovery: Discover insights across the Zoom platform via a user-friendly interface, facilitating easy access to communication archives and offering the ability to analyze, evaluate, and effortlessly export content.
  • Legal Hold: Capture and hold communications of specific individuals and manage cases through custom workflow, case management, and data export requests when legally mandated.

A future version of Zoom Compliance Manager will include:

  • Risk Detection: Monitor and detect spoken, written, or shared content at scale across supported products using intelligent detection which identify regulatory, privacy, conduct, and security risks in what was said, shown, and shared to mitigate risks.
  • Data Loss Prevention: Identify and mitigate potential risks in your communication workflows using both custom and pre-defined policies through monitoring and thorough analysis.

Zoom Compliance Manager provides compliance capabilities across the Zoom platform, including AI Companion, Meetings, Team Chat, Phone, Whiteboard, Rooms, Webinars, Events, and Contact Center. Zoom Compliance Manager is available as an add-on to Zoom customers with a paid plan.

Support for other Zoom products, including Workvivo, Zoom Revenue Accelerator, Mail, Calendar, and others, will be coming later this year.

Leveraging Theta Lake as a Leader in Compliance and Security

Zoom Compliance Manager integrates the proven compliance solution from Theta Lake, a leader in digital communications governance providing modern communication compliance and security solutions. Through Zoom-specific enhancements, customers will have the compliance benefits of Theta Lake with a frictionless Zoom experience via the administrator console.

“Our expanded compliance and security capabilities for Zoom, along with the ability to use Theta Lake technology, represents a significant milestone in our partnership,” said Anthony Cresci, SVP of GTM and Partnerships at Theta Lake. “With this new offering we are able to provide organizations with seamless and efficient access to communication and collaboration capabilities that have compliance record keeping, archiving, search, supervision, and data protection built in. I am incredibly proud of expanding the value and innovation that our partnership has delivered to our joint customers.”

Experience the Solution

Attendees of Enterprise Connect, taking place March 25-28, are encouraged to visit the Zoom booth (#407) and the Theta Lake booth (#2026). To experience a live demo of Zoom Compliance Manager, visit the Zoom booth on March 26 at 5:30 p.m. EST.

For more information, please visit the Zoom Compliance Manager landing page at https://click.zoom.us/compliance-manager

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Zoom Public Relations
Travis Isaman
press@zoom.us

GlobeNewswire Distribution ID 9066412

Posted on

Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints

Reports an Apnea-Hypopnea Index (AHI) responder rate of 63.5% on an intent to treat (ITT) basis (p=0.002)
Reports an Oxygen Desaturation Index (ODI) responder rate of 71.3% on an intent to treat (ITT) basis (p<0.001)
Median 12-month AHI reduction of 70.8%

Mont-Saint-Guibert, Belgium – March 19, 2024, 9:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the DREAM U.S. pivotal study achieved a statistically significant reduction in the co-primary endpoints of 12-month AHI responder rate, per the Sher criteria, and ODI responder rate, both on an ITT basis.

The DREAM study is a pivotal trial, being conducted under an investigational device exemption (IDE) and is designed to support the marketing authorization of the Genio® hypoglossal nerve stimulation system (HGNS) in the United States. This multicenter, prospective, open-label, interventional study enrolled 115 patients and has co-primary efficacy endpoints of the Apnea-Hypopnea Index (AHI) responder rate, per the Sher criteria, and the Oxygen Desaturation Index (ODI) responder rate, both measured at 12 months*. Subjects also were required to sleep supine for at least 60 minutes at their 12-month polysomnography test (PSG). More information regarding the study can be found in section 1.5.4 of the Company’s annual report regarding financial year 2022, which can be found on the Company’s website using the following link: Nyxoah Annual Report 2022 EN.pdf.

Study participants entered the DREAM study with a mean AHI of 28.0, mean ODI of 27.0 and mean body mass index of 28.5. At 12 months, 73 subjects were determined to be AHI responders, per the Sher criteria, resulting in an ITT AHI responder rate of 63.5% (p=0.002), and 82 subjects were determined to be ODI responders, resulting in an ODI responder rate of 71.3% (p<0.001). Subjects demonstrated a median 12-month AHI reduction of 70.8%, with similar AHI improvements in supine and non-supine sleeping positions. The safety results for the investigational treatment were favorable, with 11 serious adverse events, or SAEs, in ten subjects resulting in an SAE rate of 8.7%. Out of the 11 SAEs, three were device related and there were three explants.

“DREAM is a pivotal, multicenter, international study of Genio, a next generation HGNS technology offering patients bi-lateral stimulation with a non-implanted battery solution powered and controlled by a wearable. With the DREAM data, Genio has demonstrated positive efficacy results that OSA patients, having failed traditional medical therapies, have come to expect. Notably, Genio’s unique bilateral stimulation provides the potential for improved outcomes for a wider spectrum of OSA patients. I am excited that Nyxoah and Genio are working towards expanding options and advancing HGNS therapy for OSA, and I look forward to offering it to my patients upon FDA approval,” commented B Tucker Woodson, MD, Chief, Professor – Medical College of Wisconsin and Principal Investigator of the DREAM study.”

“I am excited to report the positive DREAM results, as they pave the way for Genio to shift the OSA treatment paradigm in the U.S. With Genio’s patient centric design, strong clinical data and commercial learnings from Europe, we are confident Nyxoah can become a leading OSA company.” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “We are finalizing the fourth and final module submission in the PMA application and I look forward to launching Genio in the U.S, pending FDA approval.”

Conference call and webcast presentation

Company management will host a conference call to discuss the DREAM results today beginning at 9:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: DREAM Results Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: DREAM Results Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please see the Company’s annual report for the financial year 2023 which will be filed on March 20, 2024 and visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; reporting data from Nyxoah’s DREAM U.S. pivotal trial; filing for FDA approval; and entrance to the U.S. market. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 22, 2023, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment

GlobeNewswire Distribution ID 1000930141

Posted on

More than 47 martyrs in two new massacres by Israeli occupation in Gaza Strip


Occupied Jerusalem, More than 47 Palestinians were martyred and dozens were injured, mostly children and women, at dawn on Wednesday, as the Israeli occupation aircraft bombed a house and a residential building in Gaza City and al-Nuseirat camp in the central Gaza Strip, on the 166th day of the ongoing Israeli aggression.

Palestinian media reported that the occupation aircraft bombed a home housing displaced persons in al-Nuseirat camp, leading to the martyrdom of 27 and the injury of others.

More than 20 Palestinians, mostly children and women, were also martyred as the occupation aircraft bombed a residential building west of Gaza City, in addition to the martyrdom of others as the occupation aircraft and its artillery bombed Sidra area, east of Gaza City.

On Wednesday evening, the Israeli occupation committed a new massacre that claimed the lives of more than 30 Palestinian, in addition to wounding dozens as a result of its bombing of Palestinian committees that distribute humanitarian aid in Gaza City.

Source: Syrian Arab News Agency

Posted on

Al Arjat 1 Local Prison: Inmate ‘M.Z’ Enjoys All Rights Guaranteed by Law

Rabat – The Al Arjat 1 local prison administration said Wednesday that the detainee (M.Z.) enjoys all the rights guaranteed to him by the law and a health follow-up carried out by the facility’s medical staff.

In a clarification issued in response to allegations made by a website about “Reducing landline telephone access to one minute ” for inmate M.Z., incarcerated at the Al Arjat 1 local prison, and the “blood tests he underwentt on a regular basis”, which, according to the website, raised concerns about his state of health, the prison administration explained that the inmate enjoys all his rights guaranteed by law, including the right to weekly use of the prison landline telephone for two 10-minute calls each.

The prisoner also benefits from family visits and a weekly visit from his lawyer, added the same source, noting that due to his age, the prisoner benefits from health monitoring by the facility’s medical staff, and even outpatient consultations carried out from time to time. It is in this context t
hat he underwent medical tests, the results of which were normal.

The clarification also noted that the prison administration’s role is limited to providing the inmate concerned with the necessary medical follow-up, whereas his state of health is a matter that directly concerns the inmate and the prison doctor or external physician, without the administration interfering.

The prison administration expressed surprise at involving the General Delegation of Prison Administration and Reintegration in the issue of the prisoner’s state of health, and at the allusion made by the aforementioned website to what it considers to be a concealment of the prisoner’s state of health. It also expressed its determination to take legal action against the website after publication of these tendentious allegations, knowing that the website has made a habit of resorting to this kind of practice.

Source: Agence Marocaine De Presse

Posted on

Morocco Launches Extensive National Campaign to Strengthen Measles Vaccination

Rabat – Morocco’s Ministry of Health and Social Protection on Wednesday launched an extensive national campaign to strengthen vaccination against measles, part of its proactive policy aimed at limiting the spread of epidemics and strengthening response.

This initiative aims to restore child vaccination to levels observed before the Covid-19 pandemic, which led to a drop in vaccination coverage rates in most regions and provinces of the Kingdom, the ministry pointed out in a press release.

The ministry strongly encourages all families to promptly review their children’s medical records in health centers and private practices to ensure the administration of the required doses for measles (at the ages of nine and eighteen months), the same source noted, stressing the need to administer two doses of vaccine to children not yet vaccinated while supplementing the doses for those who have received only one dose.

As part of its communication strategy aimed at monitoring the epidemiological evolution of measles and
its continued efforts to contain the spread of epidemiological diseases and protect public health, the ministry announces that it has monitored the emergence of new cases of measles in Morocco suggesting a more widespread expansion of the virus, the same source said.

Emphasizing the importance of this campaign as a preventive measure aimed at protecting citizens and society from the risk of measles, the ministry encourages all parties concerned to actively participate in this operation and visit health centers to receive the vaccine free of charge, the same source noted.

Source: Agence Marocaine De Presse